1. Monitoring and Modifying Treatment in PAH

2. Suggested Baseline and Serial Assessment of Patients With PAH

3. Why Modify Targeted PAH Therapy?

4. Determinants of Prognosis in PAH

5. Case Study 1: A 47-Year-Old Man With Heritable PAH (HPAH)

6. Options to Current Regimen of Inhaled Prostanoid

7. Recommendations for WHO FC II PAH Patients

8. Repeat RHC?

9. PAH: A Heterogeneous Group of Clinical Entities

10. Importance of Communication Between Specialist and Primary Care Physician

11. Case Study 2: A 51-Year-Old Woman With Scleroderma-Associated PAH (SSc PAH)

12. Six Months Later…

13. Revisiting the Initial Therapy Choice

14. Pharmacologic Agents for PAH 3 Pathways

15. The Rationale for Combination Therapy

16. AMBITION Study Design

17. AMBITION Study Primary Endpoint* Results

18. Revisiting Therapeutic Decision Made at First Follow-Up Visit

19. French Registry Low-Risk Criteria

20. COMPERA Registry Risk Stratification

21. Summary of 3 European Studies

22. Case Review and Current Status

23. GRIPHON Study Design

24. GRIPHON Titration and Dosing

25. GRIPHON Treatment Effect by Subgroup

26. Worrisome Features of This Case

27. Take-Home Points

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)

31. Abbreviations (cont)